环吡酮胺(Ciclopirox olamine) - 在研适应症：外阴阴道念珠菌病，脂溢性皮炎，真菌病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Ciclopirox Olamine Cream、Ciclopirox Olamine Gream、Ciclopirox Olamine Vaginal Suppositories

+ [13]

靶点-

作用方式-

作用机制-

治疗领域

感染皮肤和肌肉骨骼疾病泌尿生殖系统疾病+ [2]

在研适应症

外阴阴道念珠菌病脂溢性皮炎真菌病+ [2]

非在研适应症

足癣

原研机构

Medimetriks Pharmaceuticals, Inc.

在研机构

湖北科田药业有限公司

Kafrelsheikh University

Louisiana State University Health Shreveport

+ [1]

非在研机构

Perrigo Co. Plc

最高研发阶段批准上市

首次获批日期

加拿大 (1985-01-01)

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C14H24N2O3

InChIKeyMBRHNTMUYWQHMR-UHFFFAOYSA-N

CAS号41621-49-2

查看全部结构式(2)

关联

11

项与环吡酮胺相关的临床试验

NCT05647343

/ Completed临床1期

A Phase I, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers

开始日期2023-03-31

申办/合作机构

Atlas Molecular Pharma SL初创企业

CTRI/2022/01/039543

/ CompletedN/A

Evaluation of Skin Safety of a test product Ciclopirox Olamine Cream USP 1percent w/w for Primary Skin Irritation Using Skin lrritation Test (Patch Test in Humans) IS 4011 2018 Guidelines

开始日期2022-01-21

申办/合作机构

Cipla Ltd.

EUCTR2018-001633-41-DE

/ Not yet recruiting临床3期

Double-blind, randomised clinical study comparing efficacy and safety of Ciclopirox Olamine Cream 10 mg/g (Test) vs. Batrafen® Cream (Reference) vs. Vehicle in patients with skin mycoses

开始日期2019-06-18

申办/合作机构

Dermapharm AG

100 项与环吡酮胺相关的临床结果

登录后查看更多信息

100 项与环吡酮胺相关的转化医学

登录后查看更多信息

100 项与环吡酮胺相关的专利（医药）

登录后查看更多信息

864

项与环吡酮胺相关的文献（医药）

2025-02-01·Journal of Molecular Structure

Expanding the potential of pyridine scaffold for targeted therapy of cancer: Biological activity, molecular insights, and structure-activity relationship

作者: Hosamani, Ketan R ; B, Kumaraswamy ; Aishwarya, Nimmagadda Venkata Satya Sai ; I, Aayishamma ; BV, Manjushree ; Ghara, Abhishek ; Pal, Rohit ; Hosamani, Ketan R. ; Bv, Manjushree ; Matada, Gurubasavaraja Swamy Purawarga

A review.Pyridine-based ring structures are widely employed in drug design due to their significant impact on pharmacol. activity, resulting in the development of various broad-spectrum therapeutics.The US FDA approves 95 pharmaceuticals derived from pyridine, including isoniazid and ethionamide for tuberculosis, delavirdine for HIV/AIDS, abiraterone acetate for prostate cancer, tacrine for Alzheimers, ciclopirox for ringworm and athletes foot, crizotinib for cancer, nifedipine for Raynauds syndrome and premature birth, piroxicam for arthritis, and nilvadipine for hypertension.Moreover, pyridine derivatives act as an excellent candidate for targeted anticancer agents.However, pyridine anti-cancer therapies continue to encounter hurdles, including poor response rates and drug resistance.Researchers are exploring pyridine derivatives as a potential treatment for targeted anticancer therapies.To further the development of targeted anti-cancer therapies, we analyzed pyridine-targeted drugs based on target categorization.We have covered all researchers of the last six years (2019-2024) investigating pyridine derivatives as targeted anticancer treatments.The highlights of pyridine-containing drugs and their targets are listed, as well as most promising drug candidates in clin. trials containing pyridine are also discussed.This review also included explanatory insights and viewpoints from several groups involved in the creation of targeted anticancer pyridine derivatives, with an emphasis on the structure-activity relationship (SAR).We hope that the current review provides insights and perspectives for the research and development of pyridine-containing anti-cancer drugs.

2024-11-01·Computational and Theoretical Chemistry

The computational investigation of the role of pristine and metal-doped BC2N nanotubes for sensitive detection of ciclopirox drug

作者: Jassim Al-saray, Mustafa ; Muhi Hariz, Hussein ; Ahmed Said, Esraa ; Salih Jumaa, Sally ; Yadav, Anupam ; Kadhim Abosaoda, Munther ; Mohammed Ali, Yusra ; Abdulhadi Khuder, Shahad ; Ahmed Mustafa, Mohammed ; Muzahem Al-Ani, Ahmed ; Malik, Abdul ; Atiyah Altameemi, Kamil K.

Even though Ciclopirox (CPX) plays a critical role in the treatment of pancreatic, colorectal, and breast cancers, some side effects are attributable to CPX.Thus, determining the content of CPX in biol. specimens is criticalThe contribution of CPX to the activity of the intrinsic and Au-decorated BC2N nanotubes (BC2NNT) has been analyzed in this research by employing d. functional theory estimationsAccording to the results, the gold decoration resulted in a noticeable improvement in BC2NNT toward CPX and increased value of BC2NNT sensing response from 9.3 to 307.1.Furthermore, a short recovery was allowed (approx. 1.12 s) in order to desorb CPX from the Au@BC2NNT exterior.The CPX-Au@ BC2NNT interaction decreased in the aqueous solution, which led to a declined Au@BC2NNT sensing response from a value of 307.1 to 260.0.However, in accordance with our results, by employing the gold-doping process, one may transform BC2NNT into an appropriate sensor for CPX.

2024-11-01·Mycoses

First Reported Cases of Terbinafine‐Resistant Trichophyton indotineae Isolates in Israel: Epidemiology, Clinical Characteristics and Response to Treatment

作者: Shemer, Avner ; Lyakhovitsky, Anna ; Segal, Oz ; Halevi, Shiraz ; Pevzner, Keren ; Gazit, Zeala ; Baum, Sharon ; Lubitz, Irit ; Amit, Sharon ; Galili, Eran ; Astman, Nadav ; Barzilai, Aviv

ABSTRACTBackgroundTrichophyton indotineae, a newly defined species within the T. mentagrophytes/T. interdigitale complex, has emerged as an epidemiological concern worldwide. However, owing to the limitations of commonly applied fungal identification techniques, T. indotineae remains underreported. In addition, T. indotineae's response to treatment has been described in only a few studies.ObjectiveTo investigate the prevalence, clinical characteristics and treatment outcomes of terbinafine‐resistant T. mentagrophytes/T. interdigitale complex infections, as well as to detect T. indotineae cases.Patients and MethodsA retrospective cohort study was conducted on 22 patients with T. mentagrophytes/T. interdigitale complex infections between 2019 and 2023, using either culture or commercial polymerase chain reaction methods. Patient demographics, disease characteristics and treatment responses were recorded. Patients non‐responsive to oral terbinafine underwent further analyses, including DNA sequencing of the internal transcribed spacer region for accurate species identification and mutational analysis of the squalene epoxidase (SQLE) gene.ResultsThe mean age of the patients was 49.7 years (±18.2), with 54.5% men. Terbinafine‐resistant T. mentagrophytes/T. interdigitale complex infections were reported in 46.2% of the cohort (n = 6/13 patients; 9 lost to treatment response follow‐up), all of whom exhibited extensive dermatophytosis. Among the terbinafine‐resistant T. mentagrophytes/T. interdigitale isolates, all five isolates available for fungal analysis were identified as T. indotineae, harbouring SQLE single‐point mutations (Phe397Leu and Leu393Ser). Only three of the terbinafine‐resistant cases responded to oral itraconazole 200 mg/day, with two responding only to oral voriconazole and one to oral itraconazole 400 mg/day.ConclusionAll cases of T. mentagrophytes/T. interdigitale assessed in this study were identified as T. indotineae, which exhibits SQLE gene mutations. This underscores the importance of integrating methods to detect T. indotineae in routine clinical practice.

100 项与环吡酮胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01364	环吡酮胺	D01AE14 G01AX12	DBSALT001147

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
外阴阴道念珠菌病	中国	湖北科田药业有限公司	1989-01-01
脂溢性皮炎	中国	湖北科益药业股份有限公司	1989-01-01
真菌病	中国	湖北科田药业有限公司	1989-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床前	埃及	Kafrelsheikh University	2024-10-07
肿瘤	药物发现	美国	Louisiana State University Health Shreveport	2012-04-15
足癣	药物发现	-	Perrigo Co. Plc	2003-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2019	N/A	多囊肾	-	Ciclopirox-Olamine	鹹夢鹽網鏇構糧衊窪遞(衊選顧壓鑰廠鬱夢淵製) = 襯鹽鏇淵製製築選憲積構糧製齋範積獵顧鏇壓 (繭淵襯繭餘鹽鬱蓋鑰願 ) 更多	积极	2019-11-05
NCT00804193 (CTgov)	N/A	足癣	553	Ciclopirox Olamine Topical Suspension (Test Product)	醖獵壓齋觸醖夢築鑰艱(獵選積範鹹衊膚簾獵鹽) = 夢鑰廠顧鏇淵憲願顧鬱襯鹽蓋膚願齋積鬱築遞 (鬱製鹹鏇獵製構選艱醖, 遞憲淵淵願餘夢構選襯 ~ 糧積獵觸襯鑰膚艱鏇襯) 更多	-	2012-12-17
				Ciclopirox Topical Suspension 0.77%-Reference Product (Reference Product)	醖獵壓齋觸醖夢築鑰艱(獵選積範鹹衊膚簾獵鹽) = 壓壓齋糧繭遞壓壓鑰築襯鹽蓋膚願齋積鬱築遞 (鬱製鹹鏇獵製構選艱醖, 壓積積製鏇齋築簾餘願 ~ 壓夢獵簾鑰獵鑰簾簾餘) 更多
NCT00802672 (CTgov)	临床3期	足癣	561	Ciclopirox Olamine Cream (Test Product)	鹽衊醖鑰憲選獵構糧衊(鑰築鹹膚獵蓋鏇憲遞窪) = 淵壓夢鏇淵襯艱繭願簾獵構觸淵鑰願壓齋鬱襯 (製獵製襯網襯壓範鹽願, 醖築製壓鑰積餘鏇願膚 ~ 夢餘餘襯憲築製遞觸築) 更多	-	2012-06-19
				Loprox Cream 0.77% (Reference Product)	鹽衊醖鑰憲選獵構糧衊(鑰築鹹膚獵蓋鏇憲遞窪) = 襯艱衊鏇製網壓齋夢襯獵構觸淵鑰願壓齋鬱襯 (製獵製襯網襯壓範鹽願, 簾壓糧壓糧衊簾淵顧膚 ~ 獵鬱餘積蓋簾獵鹽憲憲) 更多